METTL3 and breast carcinoma: Recent studies have highlighted ZNF217's role in modulating m6A RNA methylation, showcasing its diverse mechanisms of action, from blocking the m6A "writer" METTL3 in embryonic stem cells and breast cancer cells to enhancing the transcription of the m6A "eraser" FTO in adipocytes 40-45.